Document Detail


The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
MedLine Citation:
PMID:  21083355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The iron loading related to erythrocyte transfusions is the major cause of morbidities and mortalities in patients with β-thalassemia major (β-TM). Deferasirox, an orally active iron chelator, has been reported to cause serum creatinine increases in addition to acute renal failures in elderly patients with comorbidities. The nefrotoxicities in patients using deferasirox, despite the facts that the drug is minimally excreted from kidneys and its effective chelation of iron from liver and heart, may rise the question of decomparmentalization of iron from these organs to kidneys. Thirteen patients with β-TM were included in the study (mean age 18.5 ± 7.5 years [9-33 years]). The patients received deferasirox in a dose of 34.3 ± 6.5 mg/kg [17-37 mg/kg]. Four patients (31%) exhibited consecutive increases in serum creatinine greater than 33% above baseline twice during the follow-up period. The results indicated that the earliest iron chelation starts in liver in patients receiving deferasirox. Additionally, by the 6th month of deferasirox, the status of cardiac and renal iron in chronically transfused patients with β-TM were preserved. This may indicate that the serum creatinine increases may not be attributed to iron decompartmantalization from other organs to kidneys.
Authors:
Sule Unal; Tuncay Hazirolan; Gonca Eldem; Fatma Gumruk
Related Documents :
6614135 - Zone of zero-associated phoria in patients with convergence insufficiency.
3526385 - The importance of anaemia in cerebral and uncomplicated falciparum malaria: role of com...
8318245 - Use of recombinant human erythropoietin in a jehovah's witness.
3580305 - Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relati...
16087915 - Polyneuropathy associated with interferon beta treatment in patients with multiple scle...
24768545 - Extreme variability in posterior slope of the proximal tibia: measurements on 2395 ct s...
Publication Detail:
Type:  Journal Article     Date:  2010-11-17
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  28     ISSN:  1521-0669     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-08     Completed Date:  2011-07-07     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  217-21     Citation Subset:  IM    
Affiliation:
Division of Pediatric Hematology, Hacettepe University, Ankara, Turkey. suleunal@hacettepe.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Benzoates / therapeutic use*
Child
Female
Heart / drug effects*,  physiology
Humans
Iron Chelating Agents / therapeutic use*
Iron Overload / drug therapy*,  metabolism
Kidney / drug effects*,  metabolism
Liver / drug effects*,  metabolism
Male
Prospective Studies
Treatment Outcome
Triazoles / therapeutic use*
Young Adult
beta-Thalassemia / drug therapy*,  metabolism
Chemical
Reg. No./Substance:
0/Benzoates; 0/Iron Chelating Agents; 0/Triazoles; V8G4MOF2V9/deferasirox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gastric Adenocarcinoma in a 13-Year-Old Boy: a Diagnosis not Often Seen in This Age Group.
Next Document:  Experience of Pandemic Influenza with H1N1 in Children with Leukemia.